← All organizations

Travere

For profitContributed to NME

Also known as: Retrophin, Inc. | TRAVERE

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Feb 17, 2023

Timeline

2000s

Jan 1, 2008
Travere— Founded

2010s

Jan 1, 2013
Kyalin— Acquired
Jan 1, 2014
Manchester Pharmaceuticals— Acquired

2020s

Oct 23, 2020
Aeglea Biotherapeutics— Acquired
Feb 17, 2023
sparsentan— Marketing Organization
Feb 17, 2023
sparsentan— NDA Secondary Org
Feb 17, 2023
sparsentan— NDA Organization

Drugs by trial phase (10 distinct, 17 trials)

Phase 3 (4 own, 1 via acquisition)

Phase 2 (0 own, 3 via acquisition)

Phase 1 (0 own, 2 via acquisition)

Indications

Studied for

Marketed drugs (2)

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (9)

NCT03762850Study directorPhase 3Dec 20, 2018
NCT03762850Lead sponsorPhase 3Dec 20, 2018
NCT03493685Lead sponsorPhase 3Apr 3, 2018
NCT03493685Study directorPhase 3Apr 3, 2018
NCT03041116Lead sponsorPhase 3Jun 1, 2017
NCT01613118Lead sponsorPhase 2Dec 1, 2013
NCT01115582Lead sponsorPhase 3Apr 1, 2010
NCT01438411Lead sponsorPhase 3Jan 1, 2010
NCT00007020Lead sponsorPhase 3Jan 1, 1992

Details

Founded: San Diego, CA, US Jan 1, 2008
First NDA: Feb 17, 2023
Last known activity: Feb 17, 2023

Designations held

Orphan drug
Priority review
Accelerated approval